Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Patient Information Leaflet last updated on the eMC: 13/09/2010
PIL Oculotect

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13/09/2010 and displayed until Current
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 29/01/2010 and displayed until 13/09/2010
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 11/09/2009 and displayed until 29/01/2010
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 02/01/2009 and displayed until 11/09/2009
Reasons for adding or updating:
  • Change to date of revision
Updated on 12/04/2008 and displayed until 02/01/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 12/04/2007 and displayed until 12/04/2008
Reasons for adding or updating:
  • Change to date of revision
Updated on 17/05/2005 and displayed until 12/04/2007
Reasons for adding or updating:
  • Change of manufacturer
Updated on 22/05/2003 and displayed until 17/05/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 07/01/2003 and displayed until 22/05/2003
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
   povidone k25